We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Micrus Endovascular To Market Stretch-Resistant Microcoils in Japan

By HospiMedica staff writers
Posted on 25 Dec 2007
Micrus Endovascular Corporation (San Jose, CA, USA) has announced receipt of Shonin (direct registration) approval to market its full line of stretch-resistant microcoils for the endovascular treatment of cerebral aneurysms in Japan. More...


The Micrus MicroCoil System employs a frame and fill technique, whereby the aneurysm is first framed by deploying a spherically shaped microcoil that assumes an anatomically compliant frame within the aneurysm's fragile perimeter. A MicroSphere spherical coil is used to frame the aneurysm, and is placed and deployed within the aneurysm by means of a low temperature resistive heating (RH) delivery system. In aneurysms with greater than 4 mm diameter, a second spherical coil may be deployed to strengthen the frame. Subsequent HeliPaq helical coils are then used to fill the aneurysm until it is completely occluded from the cerebral circulation. Each microcoil detachment is accomplished with the push of a button. A selection of sizes is available to enable treatment of a range of aneurysm sizes.

Sales of Micrus stretch-resistant microcoils will be managed by Goodman Co. (Nagoya, Japan), Micrus Endovascular's exclusive distributor in the Japanese market, and will also include the Cashmere, Presidio, HeliPaq, and UltiPaq stretch-resistant embolic coils.

"We are very pleased to expand our product offering in Japan where we have already developed a significant presence. Our Micrus bare platinum microcoils are currently used in approximately half of all embolic procedures and, with the approval of our stretch-resistant microcoils, we now have the opportunity to build upon this foundation,” said John Kilcoyne, Micrus Endovascular Chairman and CEO. "Additionally, we continue to work with regulatory officials in Japan to gain approval for our Cerecyte bioactive microcoils.


Related Links:
Micrus Endovascular Corporation
Goodman

Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Medical Adhesive
MED 5570U
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.